AVIR
Atea Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$353.72M
P/E Ratio
—
EPS
$-2.11
Beta
0.38
52W High
$6.45
52W Low
$2.78
50-Day MA
$5.42
200-Day MA
$4.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $192.18M |
| Gross Profit (TTM) | $-159.32M |
| EBITDA | $-189.18M |
| Operating Margin | 0.00% |
| Return on Equity | -52.60% |
| Return on Assets | -33.50% |
| Revenue/Share (TTM) | $2.31 |
| Book Value | $2.92 |
| Price-to-Book | 1.52 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 58.97 |
| EV/EBITDA | -260.47 |
| Quarterly Earnings Growth (YoY) | 264.10% |
| Quarterly Revenue Growth (YoY) | 295.20% |
| Shares Outstanding | $80.03M |
| Float | $60.24M |
| % Insiders | 13.40% |
| % Institutions | 80.14% |
Historical Volatility
HV 10-Day
104.08%
HV 20-Day
77.62%
HV 30-Day
65.19%
HV 60-Day
61.49%
HV Rank
99.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.67 target)
2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026